文献速递真菌感染

艾沙康唑在西班牙儿童和青少年中的真实世界应用

Real-life use of isavuconazole in Spanish children and adolescents.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

本研究为西班牙九家医院开展的多中心回顾性描述性研究,纳入2018至2023年接受艾沙康唑≥7天的≤18岁患者107例。艾沙康唑多作为二线治疗,53例确诊/临床诊断侵袭性真菌病患者中32例(60%)治疗反应良好,21例(40%)死亡;25%患者出现不良反应,以肝毒性最常见,10例需停药;80%患者进行治疗药物监测,其中59%的谷浓度超出2.5-5 mg/L治疗范围。

要点

  • 艾沙康唑在儿童侵袭性真菌病中多作为二线治疗,60%患者治疗反应良好。
  • 25%患者出现不良反应,肝毒性最常见,10例需停药。
  • 80%患者进行治疗药物监测,59%谷浓度超出2.5-5 mg/L范围。

核心结论

  • 艾沙康唑似乎是儿童侵袭性真菌病治疗的安全有效选择,尤其适用于一线药物失败或毒性过大时。

研究设计与样本

  • 西班牙九家医院开展的多中心回顾性描述性研究,纳入2018至2023年接受艾沙康唑≥7天的≤18岁患者107例。

主要发现

  • 107例患者中位年龄11岁,56%为男性;95例用于治疗,其中64例(67%)为二线治疗,27例(42%)因既往抗真菌药毒性而换药。
  • 53例确诊/临床诊断侵袭性真菌病患者中,32例(60%)治疗反应良好,21例(40%)死亡,其中13例死于侵袭性真菌病。
  • 27/107例(25%)患者出现不良反应,最常见为肝毒性,10例需停药。
  • 76/95例(80%)患者进行治疗药物监测,59%的谷浓度值超出治疗范围。

关键数值与推荐

  • 治疗药物监测采用谷浓度(Ctrough),治疗范围定为2.5-5 mg/L。

临床怎么用

  • 儿童侵袭性真菌病可考虑艾沙康唑,尤其一线药物失败或毒性过大时。
  • 儿童使用艾沙康唑应进行治疗药物监测,因多数谷浓度超出治疗范围。
  • 需警惕肝毒性等不良反应,必要时停药。

局限性

  • 本研究为回顾性描述性研究,未观察到谷浓度与临床结局的相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Isavuconazole (ISA) has been recently approved for the treatment of invasive aspergillosis and mucormycosis in patients aged >1 year. Prior to this approval, it was used in paediatric patients under compassionate use. The objective of this study is to describe the experience with ISA use in children. PATIENTS AND METHODS: A descriptive, retrospective, multicentre study conducted in nine Spanish hospitals, including patients aged ≤18 years who received ≥7 days of ISA between 2018 and 2023. Therapeutic drug monitoring (TDM) was performed with pre-dose [trough concentration (Ctrough)] levels measured according to local protocols. A therapeutic range of 2.5-5 mg/L was used for analysis. RESULTS: A total of 107 patients (median age: 11 years, 56% male) were included. ISA was used as a treatment (95 patients), mostly as second-line therapy (64 patients, 67%), due to toxicity from previous antifungals (27 patients, 42%). Of 53 patients with proven/probable invasive fungal disease (IFD), 32 (60%) showed a favourable response and 21 (40%) died, 13 due to IFD. Twelve patients received ISA as prophylaxis and none developed breakthrough IFD. Overall, 27/107 (25%) patients experienced adverse effects, the most common being hepatotoxicity, with 10 requiring discontinuation. TDM was performed in 76/95 patients (80%), revealing 59% of Ctrough values outside the therapeutic range. CONCLUSIONS: ISA appears to be a safe and effective option for treating IFD in children, especially when first-line agents have failed or caused excessive toxicity. Although no correlation between Ctrough and clinical outcomes was observed, the significant proportion of patients with out-of-range Ctrough emphasizes the need for TDM in paediatrics.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mendoza-Palomar N, Simó Nebot S, Roig-Soria L, et al. Real-life use of isavuconazole in Spanish children and adolescents. J Antimicrob Chemother. 2026. PMID: 41120251. doi:10.1093/jac/dkaf394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。